MAP Pharmaceuticals appoints Thomas P. McCracken

Thomas P. McCracken has joined MAP Pharmaceuticals as Vice President, Intellectual Property. MAP’s lead candidate, Levadex inhaled dihydroergotamine, is in Phase 3 trials, and McCracken will be responsible for the intellectual property program in support of its planned commercialization, according to the company. Read the MAP Pharmaceutical press release.